How ET-02 Works. Also no proof that it's better than Minoxidil. At least for now. 1/13/2025
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
community Why does Pelage PP405 receive so much attention, while Eirion ET-02 seems to be almost forgotten?
ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.
community Eirion ET-02( RS 5441) managed to defeat rodents, finally
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
Related Research
6 / 6 resultsresearch Primary cicatricial alopecia
This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.
research 26-SNP Panel Aids Guiding Androgenetic Alopecia Therapy and Provides Insight into Mechanisms of Action
This study found that using a pharmacogenetic panel with 26 SNPs can improve treatment outcomes for androgenetic alopecia, as overall response rates to minoxidil, finasteride, and dutasteride were high, and specific genetic markers predicted poor responses to these drugs.
research The diagnosis and treatment of androgenetic alopecia: a review of the most current management
This source discusses androgenetic alopecia, noting that male patients may transition from topical minoxidil to its systemic form or from finasteride to dutasteride for potentially better results, while female patients might require extensive lab testing to identify hyperandrogenism due to environmental triggers.
research Implicações da toma crónica da Finasteride para a Alopécia Androgenética no Carcinoma da Próstata
This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.
research Oral Presentations
This article discusses various aspects of hair and scalp health, ancient philosophical perspectives on hair, and causes of hair disorders in children, without reporting new clinical results.
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.